CohBar scientists have mined the mitochondrial genome and discovered novel peptides encoded in the mitochondrial DNA and generated thousands of novel analogs. We have created a proprietary platform, Mito+, which has enabled the discovery of multiple peptide programs for diseases with high unmet medical need.
After creating novel analogs of these native peptides, we utilize a broad range of proprietary activity screens that are highly predictive of human activity and disease to assess the therapeutic potential of our novel peptides.
Our analogs are then studied in in vitro and/or in vivo models to confirm their biological effects prior to the selection of a clinical candidate for further testing and ultimate entry into clinical trials.
While we look to the mitochondrial genome as the source of our therapeutic peptides, we are not focused on relatively rare diseases caused by specific mitochondrial defects or abnormalities. Rather, our screening is geared towards detecting peptides that interact with cell surface receptors and have activity in important systemic biological pathways, resulting in product candidates with the potential to impact diseases with large unmet medical needs.
Building on advances in our understanding of mitochondrial contributions to systemic processes first identified by our founders, CohBar has discovered a number of peptide families that are structurally unique and have distinct mechanisms of action, providing us with multiple independent opportunities for the successful development of novel therapeutics.